ASP Isotopes Inc. (NASDAQ: ASPI) is a company involved in the production and sale of isotopes, which are used in various industries, including medical and industrial applications. The company is listed on the NASDAQ exchange. ASPI faces competition from other isotope producers, but it aims to differentiate itself through innovation and strategic partnerships.
On March 2, 2026, Mann Paul Elliot, the Executive Chairman of ASPI, sold 162,153 shares of the company's common stock at approximately $5.44 per share. Despite this sale, Elliot still holds a substantial 7,597,385 shares. This transaction is officially documented on the SEC website, providing transparency to shareholders and potential investors.
ASPI's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -4.61, indicating negative earnings. This is further emphasized by an earnings yield of -21.67%. These figures suggest that ASPI is currently not profitable, which may concern investors looking for growth.
The company's price-to-sales ratio is 61.28, meaning investors are paying $61.28 for every dollar of sales. This high ratio, along with an enterprise value to sales ratio of 61.25, suggests that the market has high expectations for ASPI's future growth. However, the negative enterprise value to operating cash flow ratio of -21.67 indicates challenges in generating positive cash flow from operations.
ASPI's debt-to-equity ratio of 1.53 shows a significant reliance on debt financing. However, the company maintains a strong liquidity position with a current ratio of 6.14, indicating it can cover its short-term liabilities. Meanwhile, Halper Sadeh LLC is investigating potential fiduciary breaches by ASPI's officers and directors, as highlighted by PR Newswire. This investigation could lead to corporate governance reforms and other benefits for shareholders.
